118 related articles for article (PubMed ID: 23476138)
1. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9.
Gupta A; Cao W; Sadashivaiah K; Chen W; Schneider A; Chellaiah MA
ScientificWorldJournal; 2013; 2013():493689. PubMed ID: 23476138
[TBL] [Abstract][Full Text] [Related]
2. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface.
Desai B; Ma T; Zhu J; Chellaiah MA
J Cell Biochem; 2009 Sep; 108(1):272-84. PubMed ID: 19582779
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells.
Twarock S; Tammi MI; Savani RC; Fischer JW
J Biol Chem; 2010 Jul; 285(30):23276-84. PubMed ID: 20463012
[TBL] [Abstract][Full Text] [Related]
6. Membrane localization of membrane type 1 matrix metalloproteinase by CD44 regulates the activation of pro-matrix metalloproteinase 9 in osteoclasts.
Chellaiah MA; Ma T
Biomed Res Int; 2013; 2013():302392. PubMed ID: 23984338
[TBL] [Abstract][Full Text] [Related]
7. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion.
Desai B; Ma T; Chellaiah MA
J Biol Chem; 2008 May; 283(20):13856-66. PubMed ID: 18337256
[TBL] [Abstract][Full Text] [Related]
8. Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells.
Buckley ST; Medina C; Kasper M; Ehrhardt C
Am J Physiol Lung Cell Mol Physiol; 2011 Apr; 300(4):L548-59. PubMed ID: 21278261
[TBL] [Abstract][Full Text] [Related]
9. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
Liu YJ; Yan PS; Li J; Jia JF
World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA promotes malignant transformation in non-tumor cells.
Souza AG; Bastos VAF; Fujimura PT; Ferreira ICC; Leal LF; da Silva LS; Laus AC; Reis RM; Martins MM; Santos PS; Corrêa NCR; Marangoni K; Thomé CH; Colli LM; Goulart LR; Goulart VA
Sci Rep; 2020 Dec; 10(1):21674. PubMed ID: 33303880
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells.
Senbanjo LT; AlJohani H; Majumdar S; Chellaiah MA
Cell Commun Signal; 2019 Jul; 17(1):80. PubMed ID: 31331331
[TBL] [Abstract][Full Text] [Related]
12. Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44.
Guo JY; Chiu CH; Wang MJ; Li FA; Chen JY
J Biomed Sci; 2020 Jan; 27(1):2. PubMed ID: 31898491
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
Meng F; Joshi B; Nabi IR
PLoS One; 2015; 10(5):e0126056. PubMed ID: 25942420
[TBL] [Abstract][Full Text] [Related]
14. siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468).
Vahidian F; Safarzadeh E; Mohammadi A; Najjary S; Mansoori B; Majidi J; Babaloo Z; Aghanejad A; Shadbad MA; Mokhtarzadeh A; Baradaran B
Mol Biol Rep; 2020 Dec; 47(12):9541-9551. PubMed ID: 33206362
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM
Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672
[TBL] [Abstract][Full Text] [Related]
16. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
Aaltomaa S; Lipponen P; Viitanen J; Kankkunen JP; Ala-Opas M; Kosma VM
Eur Urol; 2000 Nov; 38(5):555-62. PubMed ID: 11096236
[TBL] [Abstract][Full Text] [Related]
18. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases.
Sun H; Liu T; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y
Genes Chromosomes Cancer; 2017 Aug; 56(8):598-607. PubMed ID: 28393427
[TBL] [Abstract][Full Text] [Related]
19. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis.
Xu YP; Zhao XQ; Sommer K; Moubayed P
J Zhejiang Univ Sci; 2003; 4(4):491-501. PubMed ID: 12861629
[TBL] [Abstract][Full Text] [Related]
20. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells.
Gueron G; De Siervi A; Ferrando M; Salierno M; De Luca P; Elguero B; Meiss R; Navone N; Vazquez ES
Mol Cancer Res; 2009 Nov; 7(11):1745-55. PubMed ID: 19903769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
